JAMA:早产儿依据标准疫苗接种方案后的免疫效果研究

2020-09-16 MedSci原创 MedSci原创

对于早产儿,除b型流感嗜血杆菌疫苗外,按照标准的国家疫苗接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低

早产儿由于其特殊性,可能无法从标准国家婴儿免疫计划中获得足够的保护,近日研究人员比较了早产儿与一般婴儿按照常规免疫接种计划接种疫苗后免疫原性的差异。

研究于2015-17年间在荷兰开展,296名早产儿参与研究,并与66名健康足月名婴儿进行比较,参与者按照相同的时间表接种相同的疫苗:在出生后2、3和4个月注射三剂量的白喉-破伤风类毒素-百日咳-灭活脊髓灰质炎-乙型流感嗜血杆菌-乙型肝炎联合疫苗,然后在11个月时注射加强剂,并在出生后2、4和11个月注射10价肺炎球菌疫苗。研究的主要终点包括:(1)疫苗接种完成后,高于最低保护阈值IgG抗体浓度的早产儿比例;(2)疫苗接种后的血清IgG几何平均浓度。

296例早产儿中男婴占56.1%,平均胎龄30周,220例早产儿(74.3%)完成研究。在基础三剂量疫苗接种后,所有胎龄早产儿的百日咳、白喉、破伤风和6种血清型肺炎球菌保护性IgG抗体水平在最低有效阈值的83-100%之间,40.6%的早产儿其b型流感嗜血杆菌抗体浓度在34.7%-46.2%之间,肺炎球菌血清型4、6B、18C和23F在45.8%至75.1%之间。在增加剂量接种后,除b型流感嗜血杆菌抗体(88.1%)外,95%以上的早产儿都达到了保护性抗体水平。一般而言,除百日咳毒素和肺炎球菌血清型4和19F外,与足月儿相比,早产儿疫苗诱导的抗体几何平均浓度均明显偏低。

对于早产儿,除b型流感嗜血杆菌疫苗外,按照标准的国家疫苗接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。

原始出处

Elsbeth D. M. Rouers et al. Association of Routine Infant Vaccinations With Antibody Levels Among Preterm Infants.

JAMA. September 15, 2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2022-03-12 屋顶瞄爱赏月

    学习学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2022-02-15 ms2000001254384452

    真是很获益

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2021-09-07 ms5000001266883663

    学习#学习#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2021-08-14 恣意妄为

    评论

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 CHANGE

    疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1201911, encodeId=1e6f1201911ec, content=学习学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211111/81c0b64745c644319545ec26d7ef0b34/9ddb2864d5df4dd9bf4305e380bffc96.jpg, createdBy=c7835705079, createdName=屋顶瞄爱赏月, createdTime=Sat Mar 12 09:13:19 CST 2022, time=2022-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193625, encodeId=210011936251b, content=真是很获益, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dfcf5562063, createdName=ms2000001254384452, createdTime=Tue Feb 15 14:50:45 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1015226, encodeId=d2b4101522611, content=学习<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fbc45433548, createdName=ms5000001266883663, createdTime=Tue Sep 07 01:11:43 CST 2021, time=2021-09-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007917, encodeId=ca40100e91752, content=评论, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210814/4f10b5177a794339bc579b57c6b95f39/a2c85165c1bc454aa3e382cae54ca6ee.jpg, createdBy=9b2d5573294, createdName=恣意妄为, createdTime=Sat Aug 14 21:28:33 CST 2021, time=2021-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2054245, encodeId=b7e62054245b1, content=<a href='/topic/show?id=c0772904939' target=_blank style='color:#2F92EE;'>#免疫效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29049, encryptionId=c0772904939, topicName=免疫效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18b32500069, createdName=108807375_62823127, createdTime=Mon Mar 01 14:23:20 CST 2021, time=2021-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257892, encodeId=204c125e8920e, content=<a href='/topic/show?id=f538e0501e9' target=_blank style='color:#2F92EE;'>#疫苗接种#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70501, encryptionId=f538e0501e9, topicName=疫苗接种)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Fri Sep 18 09:23:20 CST 2020, time=2020-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1036269, encodeId=6c611036269f5, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1047169, encodeId=1c4c104e16951, content=疗效只是效果的众多方面之一,还要看对患者的获益,包括生活质量等因素共同决定效果的, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 16 21:23:20 CST 2020, time=2020-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=885844, encodeId=2f698858443a, content=对于<a href='/topic/show?id=9cd45926495' target=_blank style='color:#2F92EE;'>#早产儿#</a>,除b型流感嗜血杆菌疫苗外,按照标准的国家<a href='/topic/show?id=62afe048720' target=_blank style='color:#2F92EE;'>#疫苗#</a>接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。, beContent=null, objectType=article, channel=null, level=null, likeNumber=221, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59264, encryptionId=9cd45926495, topicName=早产儿), TopicDto(id=70487, encryptionId=62afe048720, topicName=疫苗)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Wed Sep 16 19:06:48 CST 2020, time=2020-09-16, status=1, ipAttribution=)]
    2020-09-16 lovetcm

    对于#早产儿#,除b型流感嗜血杆菌疫苗外,按照标准的国家#疫苗#接种方案可达到较好的免疫预防效果,但与一般人群相比,早产儿的疫苗接种会后的抗体水平一般较低。这个研究的价值非常大,有助于对于早产儿的免疫接种的精准的指导。

    0

相关资讯

PLoS One:健康婴儿与早产儿听力筛选结果比较

最近,有研究人员比较了健康新生儿与因早产而进入婴儿重症监护室(NICU)超过5天新生儿的新生儿听力筛选(NHS)结果情况,并基于9年的数据。

JAMA:DHA与母乳喂养新生儿支气管肺发育不良风险

研究认为,在母乳喂养的孕29周前出生的早产儿中,与安慰剂相比,母体补充二十二碳六烯酸不能显著改善新生儿支气管肺发育不良风险

报告称:中国极早产儿、极低出生体重早产儿存活率明显提高

中国新生儿协作网、国家儿童医学中心新生儿专科联盟发布2019年度报告。儿科医院供图

出生时还不到一斤!25周双胎超低体重早产儿被成功救治

今年31岁的阿婷(化名)孕25周时早产生下龙凤胎,出生时两姐弟仅465克和670克,只有成年女性巴掌那么大,在广州医科大学附属第三医院新生儿科的全生命护航体系保驾护航之下,经过连续116天的救治,两姐

NEJM:Apgar评分与早产儿新生儿死亡风险

在5分钟和10分钟时的Apgar评分为不同胎龄早产儿新生儿的生存提供了的预后信息。

J Pediatr Endocrinol Metab:早产儿出生后**周循环甲状腺激素水平的变化

几十年来,早产儿短暂性甲状腺功能低下症(THOP)一直是一个争论的话题。其病理生理学尚不完全清楚,对治疗方法也缺乏共识。本研究旨在通过研究出生后第一周内甲状腺激素(TH)水平的变化趋势来更好地了解其发